相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。N-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment
Samir Mehndiratta et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency
Yingge Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent
Ritu Ojha et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Bifunctional chiral selenium-containing 1,4-diarylazetidin-2-ones with potent antitumor activities by disrupting tubulin polymerization and inducing reactive oxygen species production
Hairong Tang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents
Xiaopeng Peng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Tingting Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma
Yi Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of a chiral fluorinated azetidin-2-one as a tubulin polymerisation inhibitor with potent antitumour efficacy
Hairong Tang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
Minjeong Yeon et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells
Tao Liang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds
Ewgenij Proschak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors
Baolei Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin
Feng Gao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase
Mei-Jung Lai et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy
Yepeng Luan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site
Ling Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral beta-lactam bridged combretastatin A-4 analogues as potent antitumor agents
Pengfei Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4
Diana Lamaa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity
Hsueh-Yun Lee et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Designing multi-targeted agents: An emerging anticancer drug discovery paradigm
Rong-geng Fu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
Chiara Zagni et al.
MEDICINAL RESEARCH REVIEWS (2017)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
Design, synthesis, and biological evaluation of hydantoin bridged analogues of combretastatin A-4 as potential anticancer agents
Mao Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer
Hanlin Zeng et al.
CANCER CELL (2016)
Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research
Gabriele Giacomo Schiattarella et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Potent Antitumor Activities and Structure Basis of the Chiral β-Lactam Bridged Analogue of Combretastatin A-4 Binding to Tubulin
Pengfei Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth
Maria Jesus Perez-Perez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Effects of paclitaxel (PTX) prodrug-based self-assembly peptide hydrogels combined with suberoylanilide hydroxamic acid (SAHA) for PTX-resistant cancer and synergistic antitumor therapy
Chang Shu et al.
RSC ADVANCES (2016)
The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
Min-Wu Chao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Epigenetics: Novel Therapeutics Targeting Epigenetics
Stuart J. Conway et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors
Marije Slingerland et al.
ANTI-CANCER DRUGS (2014)
Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms
Zhaohui Liu et al.
CANCER CELL INTERNATIONAL (2014)
Polypharmacology: Challenges and Opportunities in Drug Discovery
Andrew Anighoro et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The discovery of colchicine-SAHA hybrids as a new class of antitumor agents
Xuan Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Polypharmacology in a Single Drug: Multitarget Drugs
M. L. Bolognesi
CURRENT MEDICINAL CHEMISTRY (2013)
Toxicological and metabolic considerations for histone deacetylase inhibitors
Joanna Fraczek et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
D. J. DeAngelo et al.
LEUKEMIA (2013)
Designed Multiple Ligands: Basic Research vs Clinical Outcomes
L. Costantino et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Histone deacetylases and cancer
Bruna Barneda-Zahonero et al.
MOLECULAR ONCOLOGY (2012)
Epigenetic protein families: a new frontier for drug discovery
Cheryl H. Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Microtubule-binding agents: a dynamic field of cancer therapeutics
Charles Dumontet et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Microtubule dynamics as a target in oncology
April L. Risinger et al.
CANCER TREATMENT REVIEWS (2009)
分享论文
